^™middle.

Gathering signals...

Somnomed (ASX:SOM) — Material Events

ASX:SOM · 4 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed

Significant Score 75–89

4

SomnoMed Surges with FDA Nod and 22% Revenue Growth in FY25Medium

SomnoMed delivers strong FY25 results, FDA clearance for Rest Assure®, and reaffirms FY26 guidance

27 Nov 2025 ·Annual General Meeting Presentation ·85

SomnoMed FY26 EBITDA Climbs 19% Amid CEO Shift and New Device LaunchMedium

SomnoMed FY26 revenue up 3%, EBITDA up 19%, new CEO appointed, Virtus product launched

28 Aug 2026 ·Full Year Results ·75

SomnoMed Reverses Loss with 13% Revenue Growth, Holds Dividend SteadyMedium

SomnoMed posts half-year profit turnaround with 13% revenue growth, no dividend declared

27 Feb 2026 ·Half-Year Financial Report ·75

SomnoMed Advances US Clinical Trial as Q1 Revenue Climbs 13.5%Medium

SomnoMed Q1 FY26 revenue up 13.5%, Rest Assure US clinical study advances with FDA support

30 Oct 2025 ·Quarterly Activities Report ·75

Not Assessed Low Score, or missing data

0

No articles in this tier for the last 12 months.

Market Mentions 2 - appeared in market wrap coverage

These are market wrap articles where Somnomed (ASX:SOM) was mentioned. They reflect broader market coverage, not company-specific announcements.

Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026

Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026